Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | TDP2 | O95551 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922633 | 0.80 | BRD4 (0.79) | BRD4ALDH1A1TP53HTTKDM4E | |
| SCHEMBL21830986 | 0.80 | BRD4 (0.79) | BRD4ALDH1A1TP53HTTKDM4E | |
| SCHEMBL16506112 | 0.79 | ALOX15 (0.43) | BRD4ALDH1A1TP53HTTKDM4E | |
| SCHEMBL16505468 | 0.78 | BRD4 (0.72) | BRD4TDP2ALDH1A1ELANETP53 | |
| SCHEMBL16505624 | 0.77 | NPC1 (0.40) | BRD4ALDH1A1TP53HTTHSD17B10 | |
| SCHEMBL30910867 | 0.76 | BRD4 (0.86) | BRD4ALDH1A1TP53HTTKDM4E | |
| SCHEMBL15357784 | 0.76 | BRD4 (0.68) | BRD4TDP2ELANETP53HTT | |
| SCHEMBL16505352 | 0.73 | BRD4 (0.64) | BRD4ALDH1A1TP53HTTKDM4E | |
| SCHEMBL108857 | 0.73 | BRD4 (0.63) | BRD4TDP2ELANEHTTKDM4E | |
| SCHEMBL4906896 | 0.72 | BRD4 (0.70) | BRD4TDP2ALDH1A1ELANETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3036229-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057260-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | BRD4 1974/4885TDP2 2363/4885ALDH1A1 25/4885 |
| US-20170210724-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | BRD4 1974/4885TDP2 2363/4885ALDH1A1 25/4885 |
| US-20160185797-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, NFKBIA | BRD4 1974/4885TDP2 2363/4885ALDH1A1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.